85 related articles for article (PubMed ID: 8279776)
1. Somatuline and tamoxifen in postmenopausal breast cancer patients.
Canobbio L; Cannata D; Miglietta L; Boccardo F
Ann N Y Acad Sci; 1993 Nov; 698():362-6. PubMed ID: 8279776
[No Abstract] [Full Text] [Related]
2. Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: clinical activity and effect on insulin-like growth factor-I (IGF-I) levels.
Canobbio L; Cannata D; Miglietta L; Boccardo F
Anticancer Res; 1995; 15(6B):2687-90. PubMed ID: 8669848
[TBL] [Abstract][Full Text] [Related]
3. Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients.
Mandalà M; Moro C; Ferretti G; Calabro MG; Nolè F; Rocca A; Munzone E; Castro A; Curigliano G
Anticancer Res; 2001; 21(1B):585-8. PubMed ID: 11299809
[TBL] [Abstract][Full Text] [Related]
4. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.
Pritchard KI; Shepherd LE; Chapman JA; Norris BD; Cantin J; Goss PE; Dent SF; Walde D; Vandenberg TA; Findlay B; O'Reilly SE; Wilson CF; Han L; Piura E; Whelan TJ; Pollak MN
J Clin Oncol; 2011 Oct; 29(29):3869-76. PubMed ID: 21911723
[TBL] [Abstract][Full Text] [Related]
5. Lipoprotein profile in breast cancer women: effect of tamoxifen treatment.
Dziewulska-Bokiniec A; Wojtacki J; Skokowski J; Wróblewska M
Neoplasma; 1994; 41(6):337-40. PubMed ID: 7870217
[TBL] [Abstract][Full Text] [Related]
6. Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone.
Lissoni P; Barni S; Meregalli S; Fossati V; Cazzaniga M; Esposti D; Tancini G
Br J Cancer; 1995 Apr; 71(4):854-6. PubMed ID: 7710954
[TBL] [Abstract][Full Text] [Related]
7. Use of tamoxifen for breast cancer: twenty-eight years later.
Jaiyesimi IA; Buzdar AU; Decker DA; Hortobagyi GN
J Clin Oncol; 1995 Feb; 13(2):513-29. PubMed ID: 7844613
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen versus tamoxifen + mitoxantrone treatment in metastatic breast cancer.
Kars A; Baltali E; Tekuzman G; Firat D; Alakavuklar M
J Chemother; 1989 Jul; 1(4 Suppl):1196-7. PubMed ID: 16312831
[No Abstract] [Full Text] [Related]
9. Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients.
Lønning PE; Hall K; Aakvaag A; Lien EA
Cancer Res; 1992 Sep; 52(17):4719-23. PubMed ID: 1380889
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial on tamoxifen continuation during second-line hormone therapy in breast cancer.
Pronzato P; Bertelli G; Rosso M
Ann N Y Acad Sci; 1993 Nov; 698():357-61. PubMed ID: 8279775
[No Abstract] [Full Text] [Related]
11. Tamoxifen and megestrol acetate for postmenopausal breast cancer: diverging effects on liver proteins, androgens, and glucocorticoids.
Löfgren L; Wallberg B; Wilking N; Fornander T; Rutqvist LE; Carlström K; von Schoultz B; von Schoultz E
Med Oncol; 2004; 21(4):309-18. PubMed ID: 15579914
[TBL] [Abstract][Full Text] [Related]
12. A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma.
Bajetta E; Procopio G; Ferrari L; Martinetti A; Zilembo N; Catena L; Alú M; Della TS; Alberti D; Buzzoni R
Cancer; 2002 Jan; 94(2):299-304. PubMed ID: 11900215
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer.
Budd GT; Adamson PC; Gupta M; Homayoun P; Sandstrom SK; Murphy RF; McLain D; Tuason L; Peereboom D; Bukowski RM; Ganapathi R
Clin Cancer Res; 1998 Mar; 4(3):635-42. PubMed ID: 9533531
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
[TBL] [Abstract][Full Text] [Related]
15. Detection of endometrial cancer in asymptomatic postmenopausal breast cancer patient treated with tamoxifen: a case report.
Sinawat S; Chiyabutra T; Kleabkaew P
J Med Assoc Thai; 2001 Jul; 84(7):1033-6. PubMed ID: 11759963
[TBL] [Abstract][Full Text] [Related]
16. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer.
Buzdar AU
Oncologist; 2003; 8(4):335-41. PubMed ID: 12897330
[TBL] [Abstract][Full Text] [Related]
17. Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability.
Mouridsen H; Sun Y; Gershanovich M; Perez-Carrion R; Becquart D; Chaudri-Ross HA; Lang R
Oncologist; 2004; 9(5):489-96. PubMed ID: 15477633
[TBL] [Abstract][Full Text] [Related]
18. Ovarian volume in postmenopausal breast cancer patients treated with tamoxifen.
Cohen I; Altaras MM; Beyth Y; Zalel Y; Shapira J; Yigael D; Tepper R
Gynecol Oncol; 1997 Jan; 64(1):105-8. PubMed ID: 8995556
[TBL] [Abstract][Full Text] [Related]
19. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
[TBL] [Abstract][Full Text] [Related]
20. Adenomyosis in postmenopausal breast cancer patients treated with tamoxifen: a new entity?
Cohen I; Beyth Y; Tepper R; Figer A; Shapira J; Cordoba M; Yigael D; Altaras MM
Gynecol Oncol; 1995 Jul; 58(1):86-91. PubMed ID: 7789896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
